Certain commonly prescribed sleeping pills are associated with a more than fourfold increased risk of death, even among those taking fewer than 18 doses a year, indicates research published in the online journal BMJ Open.
And these drugs are also associated with a significantly increased risk of cancer among those taking high doses, the study shows.
In 2010 between one in 20 and one in 10 adults took a sleeping pill in the US alone, say the authors, who tracked the survival of over 10,500 people with a range of underlying conditions, who were prescribed a range of sleeping pills for an average of 2.5 years between 2002 and 2007.
The drugs included benzodiazepines, such as temazepam; non-benzodiazepines, such as zolpidem, eszopiclone, and zaleplon; barbiturates; and sedative antihistamines.
The survival of these patients, whose average age was 54, was then compared with that of over 23,500 people matched for age, sex, lifestyle factors, and underlying health problems, but who had not been prescribed sleeping pills over the same period.
After taking account of factors likely to influence the results, including age, sex, weight, lifestyle, ethnicity and previously diagnosed cancer, the results pointed to a link between these drugs and an increased risk of death, even at relatively low doses.
Those prescribed up to 18 doses a year were more than 3.5 times as likely to die as those prescribed none, while those prescribed between 18 and 132 doses were more than four times as likely to do so.
And those taking the most doses (132+ a year) were more than five times as likely to die as those prescribed none, indicating that the level of risk rose in tandem with increasing doses, say the authors.
These associations were found in every age group, but were greatest among those aged 18 to 55.
Supplementary material posted alongside the paper shows that, although the overall numbers of deaths in each group were quite small, there were clear differences among them.
For example, there were 265 deaths among 4,336 people taking zolpidem, compared with 295 deaths among the 23,671 people who had not taken sedatives or sleeping pills.
Those taking the highest number of doses were also at greater risk of developing several types of cancer, and 35% more likely to be diagnosed with any type of cancer, overall. This association was not explained by pre-existing poor health, the data showed.
The authors point out that studies showing association don't necessarily prove cause and effect. But their findings back up previous research showing an increased risk of death among users of sleeping pills, they say.
Agreement is beginning to build that alternatives to sleeping pills for the treatment of insomnia may be warranted, they write.
And they ask if it isn't time to reconsider "whether even the short term use of hypnotics, as given qualified approval in National Institute for Health and Clinical Excellence [NICE] guidance, is sufficiently safe."
BMJ Open editor in chief, Dr Trish Groves, comments: "Although the authors have not been able to prove that sleeping pills cause premature death, their analyses have ruled out a wide range of other possible causative factors. So these findings raise important concerns and questions about the safety of sedatives and sleeping pills."
BMJ-British Medical Journal: http://www.bma.org
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
A woman is thought to be spreading Ebola in a remote village. So health workers spend four hours trekking through the bush to track her down. By the time they make it, it's too late.
Doctors have used perfect replicas of childrens' hearts to uncover and repair hidden defects
An experiment testing people’s altruism in the face of electric shocks is clear on one thing: we are drawn to these little blasts
Researchers gear up tests in West Africa to see whether blood from Ebola survivors can help people who are sick with the disease. This is part of a broader effort to test therapies in West Africa.
The virus's foray into Europe coincides with peak production of Christmas turkeys, the poultry species most vulnerable to bird flu
A novel kind of nanoparticle could lead to more effective cancer treatments.Patients and doctors often don’t know if surgery to remove cancerous tissue was successful until scans are performed months later. A new kind of nanoparticle could show patients if they’re in the clear much earlier.
One challenge in evaluating the effectiveness of different medical procedures, is that patients behave differently after different procedures. Is this true for patients getting heart surgery?
It is only in the aftermath of treatment that survivors discern that their adrenalin alone wont fuel the rest of their recovery. For many, surviving cancer is followed by even more hardship
Just down the road from Facebook and Google, Dr. Phil Wagner runs a laboratory dedicated to optimizing the performance of some of the world's top athletes. At Sparta Performance Science in Menlo Park, California, Wagner and his team bring the spirit of Silicon Valley to bear on the athletic world, helping athletes find the tiny advantages that add to championships. Join us for a trip inside the lab to see where sports meets science.
Pieter Cohen, an internist in Massachusetts, got interested in dietary supplements several years ago, when some of his …